Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth.

abstract：:Glioma is the most common tumor in the central nervous system that portends a poor prognosis. Key genes negatively related to survival may provide targets for therapy to improve the outcome of glioma. Here, we report a protein-coding gene CLEC5A, which is the top 1 gene by univariate Cox regression analysis of 524 pri...

journal_title：Cancer gene therapy

authors： Tong L,Li J,Choi J,Pant A,Xia Y,Jackson C,Liu P,Yi L,Boussouf E,Lim M,Yang X

更新日期：2020-09-01 00:00:00

abstract：:A nonviral gene delivery vector has been developed in our laboratory based on the cationic polymer, poly(2-(dimethylethylamino)ethyl methacrylate) (p(DMAEMA)). p(DMAEMA)-based polyplexes have been successfully used for the transfection of OVCAR-3 cells in vitro. However, these polyplexes were unable to transfect OVCAR...

journal_title：Cancer gene therapy

authors： Mastrobattista E,Kapel RH,Eggenhuisen MH,Roholl PJ,Crommelin DJ,Hennink WE,Storm G

更新日期：2001-06-01 00:00:00

abstract：:Clear cell renal cell carcinoma (ccRCC) is the highest mortality, invasion, and metastasis subtype of renal cell carcinoma. Bone morphogenetic protein (BMP) family has recently emerged as a group of cancer-related proteins in multiple pathogenesis of cancers. Currently, little is known about the prediction role of BMP...

journal_title：Cancer gene therapy

authors： Xiao W,Wang X,Wang T,Xing J

更新日期：2020-05-01 00:00:00

abstract：:EGP-2, also known as Ep-CAM, is expressed at high levels on the surface of most carcinomas and is therefore considered an attractive target for anticancer strategies. To explore the mechanisms regulating the expression of EGP-2, sequences 3.4 kb upstream of the transcription start site were isolated and assayed for th...

journal_title：Cancer gene therapy

authors： McLaughlin PM,Trzpis M,Kroesen BJ,Helfrich W,Terpstra P,Dokter WH,Ruiters MH,de Leij LF,Harmsen MC

更新日期：2004-09-01 00:00:00

abstract：:Specificity is a prerequisite for systemic gene therapy of hepatocarcinoma. In vitro, the tumor-specific viral death effector Apoptin selectively induces apoptosis in malignant hepatic cells. Intratumoral treatment of xenografted subcutaneous hepatomas with Apoptin results in tumor regression. Here, we report a system...

journal_title：Cancer gene therapy

authors： Peng DJ,Sun J,Wang YZ,Tian J,Zhang YH,Noteborn MH,Qu S

更新日期：2007-01-01 00:00:00

abstract：:Thymidylate synthase (TS) catalyzes de novo production of thymidylate for DNA synthesis and cell proliferation. As such, TS has been a target of antitumor chemotherapy for many years. Our laboratory has identified several antisense oligodeoxynucleotides (ODNs) that downregulate TS mRNA and protein, inhibit cell prolif...

journal_title：Cancer gene therapy

authors： Berg RW,Ferguson PJ,Vincent MD,Koropatnick DJ

更新日期：2003-04-01 00:00:00

abstract：:Engineered retroviruses are widely used vectors for cancer gene therapy approaches. However, the ability to target cells of therapeutic interest while controlling the expression of the transferred genes would improve both the efficiency and the safety of viral vectors. In this study, we investigated the ability of a r...

journal_title：Cancer gene therapy

authors： Nguyen TH,Loux N,Dagher I,Vons C,Carey K,Briand P,Hadchouel M,Franco D,Jouanneau J,Schwall R,Weber A

更新日期：2003-11-01 00:00:00

abstract：:Oncolytic adenoviruses are promising anticancer agents. To study and optimize their tumor-killing potency, genuine tumor models are required. Here we describe the use of the chicken chorioallantoic membrane (CAM) tumor model in studies on oncolytic adenoviral vectors. Suspensions of human melanoma, colorectal carcinom...

journal_title：Cancer gene therapy

authors： Durupt F,Koppers-Lalic D,Balme B,Budel L,Terrier O,Lina B,Thomas L,Hoeben RC,Rosa-Calatrava M

更新日期：2012-01-01 00:00:00

abstract：:Aberrantly expressed microRNAs (miRNAs) are involved in breast tumorigenesis. It is still unclear if and how miRNAs-221/222 are implicated in breast cancer and the resistance to estrogen receptor modulator tamoxifen. We investigated the roles and mechanisms of miR-221/222 in breast cancer cells, particularly in modula...

journal_title：Cancer gene therapy

authors： Gan R,Yang Y,Yang X,Zhao L,Lu J,Meng QH

更新日期：2014-07-01 00:00:00

abstract：:Targeting tumor vasculature represents an interesting approach for the treatment of solid tumors. The alpha v beta 3 integrins have been found to be specifically associated with angiogenesis in tumors. By using bacteriophage display technology, Ruoslahti et al found that a group of peptides containing the RGD (Arg-Gly...

journal_title：Cancer gene therapy

authors： Li J,Ji J,Holmes LM,Burgin KE,Barton LB,Yu X,Wagner TE,Wei Y

更新日期：2004-05-01 00:00:00

abstract：:Let-7 miRNAs are involved in carcinogenesis and tumor progression through their roles in maintaining differentiation and normal development. However, there is little research focusing on the effects of let-7 on Wnt-activated self-renewal of breast cancer stem cells. By analyzing the expression levels of let-7 family m...

journal_title：Cancer gene therapy

authors： Sun X,Xu C,Tang SC,Wang J,Wang H,Wang P,Du N,Qin S,Li G,Xu S,Tao Z,Liu D,Ren H

更新日期：2016-04-01 00:00:00

abstract：:The success of cancer gene therapies requiring in vivo gene transfer is severely hampered by the low efficacy of gene transfer, which has been difficult to improve. We therefore established a novel strategy to increase the share of transduced cells post gene transfer. We hypothesized that in vivo selection of tumor ce...

journal_title：Cancer gene therapy

authors： Unger MM,Wahl J,Ushmorov A,Buechele B,Simmet T,Debatin KM,Beltinger C

更新日期：2007-01-01 00:00:00

abstract：:Newcastle disease virus (NDV), an avian paramyxovirus, has a potential oncolytic effect that may be of significance in the treatment of a variety of cancer diseases. An attenuated lentogenic isolate of NDV (HUJ) demonstrated a selective cytopathic effect upon a panel of human and mouse lung tumor cells, as compared to...

journal_title：Cancer gene therapy

authors： Yaacov B,Eliahoo E,Lazar I,Ben-Shlomo M,Greenbaum I,Panet A,Zakay-Rones Z

更新日期：2008-12-01 00:00:00

abstract：:A number of monoclonal antibodies (mAbs) have been studied for their ability to enhance immune responses. Although these antibodies are effective in pre-clinical and clinical studies, they are costly and have occasionally been associated with adverse effects such as autoimmunity and cytokine storm. Numerous studies ha...

journal_title：Cancer gene therapy

authors： Boczkowski D,Lee J,Pruitt S,Nair S

更新日期：2009-12-01 00:00:00

abstract：:Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC are very few and suboptimal. Oncolytic virotherapy using replication-competent vaccinia virus (VACV) is a promising new strategy to treat human cancers. The ability of oncolytic VACV GLV-1h...

journal_title：Cancer gene therapy

authors： Pugalenthi A,Mojica K,Ady JW,Johnsen C,Love D,Chen NG,Aguilar RJ,Szalay AA,Fong Y

更新日期：2015-12-01 00:00:00

abstract：:We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the transcriptional control of the tetO/promoter. Human melanoma cel...

journal_title：Cancer gene therapy

authors： Pitzer C,Schindowski K,Pomer S,Wirth T,Zöller M

更新日期：1999-03-01 00:00:00

abstract：:Previous studies have indicated that the cytokine interleukin (IL)-21 may induce both innate and adaptive immune responses against tumors. The goal of this study was to evaluate a new adoptive immunotherapy strategy that combined lymphocytes from mice immunized with a murine myeloma vaccine secreting murine IL-21 (mIL...

journal_title：Cancer gene therapy

authors： Dou J,Wu Y,Wang J,Zhao F,Chu L,Liu C,Wen P,Hu W,Hu K,He XF,Gu N

更新日期：2010-10-01 00:00:00

abstract：:As an initial assessment of the feasibility of employing the adenovirus serotype 3 (Ad3) fiber knob as a locale for introducing a tropism-modifying motif, we generated an adenoviral vector containing a six-histidine tag genetically fused to the carboxy-terminus of the Ad3 fiber knob. The heterologous tag proved to be ...

journal_title：Cancer gene therapy

authors： Uil TG,Seki T,Dmitriev I,Kashentseva E,Douglas JT,Rots MG,Middeldorp JM,Curiel DT

更新日期：2003-02-01 00:00:00

abstract：:Multicomponent lipoplexes have recently emerged as especially promising transfection candidates, as they are from 10 to 100 times more efficient than binary complexes usually employed for gene delivery purposes. Previously, we investigated a number of chemical-physical properties of DNA-lipid complexes that were propo...

journal_title：Cancer gene therapy

authors： Marchini C,Pozzi D,Montani M,Alfonsi C,Amici A,Candeloro De Sanctis S,Digman MA,Sanchez S,Gratton E,Amenitsch H,Fabbretti A,Gualerzi CO,Caracciolo G

更新日期：2011-08-01 00:00:00

abstract：:Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer deaths in Americans. The high mortality rate is mainly attributed to the invasiveness and metastasis of advanced prostate cancer. Targeting the molecules involved in metastasis could be an effective mode of treatment f...

journal_title：Cancer gene therapy

authors： Nalla AK,Gorantla B,Gondi CS,Lakka SS,Rao JS

更新日期：2010-09-01 00:00:00

abstract：:Herpes simplex viruses (HSVs) are important pathogens and ideal for gene therapy due to its large genome size. Previous researches on HSVs were hampered because the technology to construct recombinant HSVs were based on DNA homology-dependent repair (HDR) and plaque assay, which are inefficient, laborious, and time-co...

journal_title：Cancer gene therapy

authors： Wang D,Wang XW,Peng XC,Xiang Y,Song SB,Wang YY,Chen L,Xin VW,Lyu YN,Ji J,Ma ZW,Li CB,Xin HW

更新日期：2018-06-01 00:00:00

abstract：:A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of interferon-α (IFNα) being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic ...

journal_title：Cancer gene therapy

authors： Benedict WF,Fisher M,Zhang XQ,Yang Z,Munsell MF,Dinney CN

更新日期：2014-03-01 00:00:00

abstract：:Direct intratumoral injection of a lipid/DNA complex encoding an allogeneic major histocompatibility complex (MHC) class I molecule leads to regression of both an immunogenic murine tumor and also melanoma lesions in some patients. We have sought to understand the mechanism(s) for this augmentation of antitumor activi...

journal_title：Cancer gene therapy

authors： Fox BA,Drury M,Hu HM,Cao Z,Huntzicker EG,Qie W,Urba WJ

更新日期：1998-09-01 00:00:00

abstract：:The p16INK4 tumor suppressor gene encodes a protein that inhibits cyclin-dependent kinase 4, and its homologous deletion is common in human breast cancer. p16INK4 gene transfer has been reported to be efficacious in inducing growth inhibition of various human tumors such as brain, lung, prostate, and esophageal cancer...

journal_title：Cancer gene therapy

authors： Campbell I,Magliocco A,Moyana T,Zheng C,Xiang J

更新日期：2000-09-01 00:00:00

abstract：:Survivin is expressed in most cancers but is undetectable in differentiated adult cells, and plays an important role both in the suppression of apoptosis and mitotic spindle checkpoint; thus it has attracted great interest as a potential drug target. In this study, we investigated the antigene and antiproliferative ef...

journal_title：Cancer gene therapy

authors： Shen C,Buck A,Polat B,Schmid-Kotsas A,Matuschek C,Gross HJ,Bachem M,Reske SN

更新日期：2003-05-01 00:00:00

abstract：:As of January 2005, there were 1020 gene therapy clinical trials ongoing worldwide with 675 or 66.2% devoted to cancer gene therapy. The majority are occurring in the US and Europe (http://www.wiley.co.uk/genetherapy/clinical/). At the present time, to our knowledge there are no trials that employ gene delivery of Fas...

journal_title：Cancer gene therapy

authors： Norris JS,Bielawska A,Day T,El-Zawahri A,ElOjeimy S,Hannun Y,Holman D,Hyer M,Landon C,Lowe S,Dong JY,McKillop J,Norris K,Obeid L,Rubinchik S,Tavassoli M,Tomlinson S,Voelkel-Johnson C,Liu X

更新日期：2006-12-01 00:00:00

abstract：:Lung metastases are a frequent complication of osteosarcoma and a treatment that would reduce the severity of this complication would be of great benefit to patients. We have used a formulation consisting of polyethyleneimine (PEI) and a p53 gene administered in aerosol to treat established lung micrometastases as a m...

journal_title：Cancer gene therapy

authors： Densmore CL,Kleinerman ES,Gautam A,Jia SF,Xu B,Worth LL,Waldrep JC,Fung YK,T'Ang A,Knight V

更新日期：2001-09-01 00:00:00

abstract：:Oncolytic herpes simplex virus (oHSV)-1-based vectors selectively replicate in tumor cells causing direct killing, that is, oncolysis, while sparing normal cells. The oHSVs are promising anticancer agents, but their efficacy, when used as single agents, leaves room for improvement. We hypothesized that combining the d...

journal_title：Cancer gene therapy

authors： Passer BJ,Cheema T,Wu S,Wu CL,Rabkin SD,Martuza RL

更新日期：2013-01-01 00:00:00

abstract：:In order to determine the potential of alternative splicing as a means of targeting the expression of therapeutic genes to tumor cells in vivo, a series of episomal plasmid-based "splice-activated gene expression" (pSAGE) vectors was generated, which contain minigene cassettes composed of various combinations of the t...

journal_title：Cancer gene therapy

authors： Hayes GM,Carpenito C,Davis PD,Dougherty ST,Dirks JF,Dougherty GJ

更新日期：2002-02-01 00:00:00

abstract：:Malignant tumors express tumor-related antigens, but effective antitumor immunity does not occur in the primary host. One hypothesis is that there is insufficient stimulation of T-cell responses due to ineffective antigen presentation. An approach to overcome these deficiencies is to modify tumor cells to express majo...

journal_title：Cancer gene therapy

authors： Hock RA,Reynolds BD,Tucker-McClung CL,Heuer JG

更新日期：1996-09-01 00:00:00